Postmarketing surveillance of oral terbinafine in the UK: Report of a large cohort study

British Journal of Clinical Pharmacology

Volumn 42, Issue 5, 1996, Pages 559-565

  O'Sullivan, D P ^a   Needham, C A ^a   Bangs, A ^a   Atkin, K ^a   Kendall, F D ^a  

^a Frimley Business Park   (United Kingdom)

Author keywords

postmarketing surveillance; safety; source data verification; taste disturbance; terbinafine

Indexed keywords

TERBINAFINE;

ARTICLE; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; SIDE EFFECT; TASTE DISORDER; UNITED KINGDOM;

EID: 0029828328     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00049.x     Document Type: Article

References (11)

1. Clayton YM. In vitro activity of terbinafine. Clin Exp Dermatol 1989; 14: 101-103.
2. Petranyi G. Ryder NS, Stutz A. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science 1984; 224: 1239-1241.
3. Ryder NS. Terbinafine: Mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992; 126 (Suppl 39): 2-7.
4. Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991; 32: 624-626.
5. Savin RC, Zaias N. Treatment of chronic moccasin-type tinea pedis with terbinafine: A double-blind, placebocontrolled trial. J Am Acad Dermatol 1990; 23 (4 Pt 2, Suppl): 804-807.
6. White JE, Perkins PJ, Evans EGV. Successful 2-week treatment with terbinafine (Lamisil®) for moccasin tinea pedis and tinea manuum. Br J Dermatol 1991; 125:260-262.
7. Goodfield MJD, Andrew L, Evans EGV. Short term treatment of dermatophyte onychomycosis with terbinafine. Br Med J 1992; 304: 1151-1154.
8. Villars V, Jones TC. Present status of the efficacy and tolerability of terbinafine (Lamisil®) used systemically in the treatment of dermatomycoses of skin and nails. J Dermatol Treat 1990; 1 (Suppl 2): 33-38.
9. Joint committee of ABPI, BMA, CSM, and RCGP. Guidelines on postmarketing surveillance. Br Med J 1988; 296: 399-400.
10. Read JD, Benson TComprehensive Coding. Br J Healthcare Computing 1986; 3(2): 22-25.
11. Waller PC, Wood SM, Langman MJS, Breckenridge AM, Rawlins MD. Review of company postmarketing surveillance studies. Br Med J 1992; 304: 1470-1472.